SKU: F043

Size  
Quantity:
 
Price: make selection(s)
Description

Fosfomycin tromethamine is a broad-spectrum organophosphonate antibiotic with in vitro activity against most urinary tract pathogens.  It is active against E. coliCitrobacter,EnterobacterKlebsiellaSerratia and Enterococcus.  

    CAS Number

    78964-85-9

    Molecular Formula

    C7H18NO7P

    Molecular Weight

    259.19 g/mol

    Mechanism of Action

    Fosfomycin tromethamine inhibits bacterial cell (peptidoglycan) synthesis. Specifically, it inhibits uridine diphospho-N-acetl-D-glucosamine enolpyruvyl transferase (MurA), thereby blocking the condensation of uridine diphosphate-N-acetylglucosamine, one of the first steps in peptidoglycan synthesis.

    Storage Conditions

    2-8┬░C, airtight, protect from light

    Tariff Code

    2941.90.9000

    Spectrum

    Broad spectrum against both Gram-positive and Gram-negative pathogens

Applications

    Eukaryotic Cell Culture Applications

    Investigators examined the effect of Fosfomycin on the immune system, specifically the in vitro function of human T cells, and was found to exert its action on the late stage of T-cell activation.  It inhibited the proliferation of human lymphocytes induced by polyclonal T-cell mitogens.  It suppressed mixed lymphocyte reaction and the production of interleukin-2 by T-cells.  Fosfomycin also inhibited the expression of IL-2 receptor and transferrin receptor on T-cell surfaces.   This property widens the therapeutic indices as it could be combined with immunosuppressants in organ transplantation (Morikawa et al, 1993).

Specifications

    Form

    Powder

    Appearance

    White or almost white powder

    Source

    Streptomyces fradiae

References

    References

    Baum EZ et al (2001)  Identification and characterization of new inhibitors of the Escherichia coli MurA enzyme. Antimicrob. Agents Chermother. 45(11):3182-3188  PMID 11600375

    de Cueto M et al (2006) In vitro activity of Fosfomycin against extended-spectrum—lactamase producing Escherichia coli and Klebsiella pneumoniae: Comparison of susceptibility testing procedures. Antimicrob. Agents and Chemother 50:368-370

    Falagas ME and Kastaris AC (2010)  Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: A systematic review.   Lancet Infect. Dis. 10(1): 43-50 PMID 20129148

    Grif K et al (2001) In vitro activity of Fosfomycin in combination with various antistaphylococcal substances. J Antimicrob. Chemother 48:209-217

    Kahan FM et al (1974) The mechanism of action of Fosfomycin (phosphonomycin) Ann. NY Acad Sci 235:364-386

    Morikawa K,  Oseko F, Morikawa S, Sawada M(1993)  Immunosuppressive activity of fosfomycin on human T-lymphocyte function in vitro.  Antimicrob. Agents Chemother. 37(12): 2684-2687  PMID 7509146

Other Items In This Category